ZIPBIO
Live / Applied — First extension granted (statement of use) (as of 08 Jan 2026)
What this means for you
Not registered yet, but its 15 Oct 2024 filing date beats anything filed after it. If it registers, the owner can stop confusingly similar uses in the classes it covers.
Record
- Serial number
- 98801864
- Mark type
- Stylized text
- Filed
- 15 Oct 2024
- Published for opposition
- 13 May 2025
- Attorney of record
- Aaron D. Hendelman
Goods and services
- Class 005 — Pharmaceuticals: pharmaceutical preparations for the treatment of ophthalmological diseases and disorders; therapeutic proteins for medical use for the treatment of ophthalmological diseases and disorders; biologics for medical use, namely, biological preparations for the treatment of ophthalmological diseases and disorders; pharmaceutical preparations, biological preparations, clinical medical reagents and therapeutic proteins for use in the treatment of genetic-based and cell-based diseases and disorders; pharmaceutical preparations, biological preparations, clinical medical reagents and therapeutic proteins for use in gene therapy, cell therapy, gene diagnosis, cell diagnosis, gene testing and cell testing; pharmaceutical preparations, biological preparations, clinical medical reagents and therapeutic proteins for the treatment of autoimmune, cardiovascular, central nervous system, endocrine, gastrointestinal, genetic, infectious, inflammatory, kidney, liver, menopausal, metabolic, musculoskeletal, neurodegenerative, neurological, neuromuscular and viral diseases and disorders; pharmaceutical preparations, biological preparations, clinical medical reagents and therapeutic proteins for the treatment of blood disorders, bone growth disorders, skin disorders, arthritis, cancer, hypertension, pain, stroke, obesity and diabetes; vaccines for human use; biological therapeutic preparations for use as vaccines
- Class 042 — Scientific and technological services: research and development relating to pharmaceuticals for the treatment of ophthalmological diseases and disorders; scientific research and development in connection with therapeutic proteins for use in pharmaceutical products; medical research and product development in the fields of biotechnology, drug discovery, pharmaceuticals, scientific research, biological preparations and protein therapeutics; research and development relating to pharmaceutical preparations, biological preparations and therapeutic proteins for the treatment of autoimmune, cardiovascular, central nervous system, endocrine, gastrointestinal, genetic, infectious, inflammatory, kidney, liver, menopausal, metabolic, musculoskeletal, neurodegenerative, neurological, neuromuscular and viral diseases and disorders; research and development in the field of gene therapy, gene diagnosis and gene testing; biological research; chemical research; medical and scientific research, namely, conducting clinical trials for others; scientific research; scientific laboratory services
Owner
- Zip Bio Inc., Brookline, MA, US
- Zip Bio Inc., Brookline, MA, US
Prosecution history
- 08 Jan 2026 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 08 Jan 2026 — SOU EXTENSION 1 GRANTED
- 07 Jan 2026 — SOU EXTENSION 1 FILED
- 07 Jan 2026 — SOU TEAS EXTENSION RECEIVED
- 08 Jul 2025 — NOA E-MAILED - SOU REQUIRED FROM APPLICANT
- 13 May 2025 — OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
- 13 May 2025 — PUBLISHED FOR OPPOSITION
- 07 May 2025 — NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
- 14 Apr 2025 — APPROVED FOR PUB - PRINCIPAL REGISTER
- 28 Mar 2025 — TEAS/EMAIL CORRESPONDENCE ENTERED
- 28 Mar 2025 — CORRESPONDENCE RECEIVED IN LAW OFFICE
- 28 Mar 2025 — TEAS RESPONSE TO OFFICE ACTION RECEIVED
- 26 Mar 2025 — NOTIFICATION OF NON-FINAL ACTION E-MAILED
- 26 Mar 2025 — NON-FINAL ACTION E-MAILED
- 26 Mar 2025 — NON-FINAL ACTION WRITTEN